6 results about "Enterobacter aerogene" patented technology

The invention belongs to the technical field of medicines, relates to an avibactam-containing antibacterial composition and application thereof, and particularly provides application of avibactam or pharmaceutically acceptable salts thereof and carbapenem antibiotics in preparation of medicines for treating or preventing bacterial infection. The invention relates to application of carbapenem antibiotics, in particular to application of carbapenem antibiotics in preparation of medicines for treating infection caused by escherichia coli, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and enterobacter aerogenes, so as to solve the problem of drug resistance of carbapenem antibiotics.

The application discloses a specific phosphorus-dissolving bacterial strain combination, a carrier for the strain combination and a co-cultivation method, and the strain combination is composed of Burkholderia cenocepacia, Burkholderia pyrrocinia, Enterobacter aerogenes and Bacillus subtilis, and the carrier is a mixture of discarded peanut shells and sugarcane residues. The application determines the dominant carrier suitable for the growth of the specific strain combination, meets the strain type and the number of living bacteria of the microbial agent product stipulated by the country, and effectively solves the problems of easy inactivation of the phosphorus-dissolving microbial strain in liquid, short preservation time and high transportation cost through the optimal cultivation process system of the specific phosphorus-dissolving microbial strain combination on the carrier. The strain activity and proliferation are maintained through the fermentation of the strain on the solid carrier, so as to meet the market demand for the phosphorus-dissolving microbial agent product.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The invention discloses application of electrochemical active bacteria sensitive to heavy metal pollutants in detection of water quality biotoxicity, and belongs to the technical field of water quality biotoxicity detection.After the electrochemical active bacteria are exposed to toxic pollutants, the water quality biotoxicity is determined according to an electric signal inhibition rate; the toxic pollutants are heavy metal pollutants; the electrochemical active bacteria are enterobacter aerogenes or enterobacter cloacae and are selected from enterobacter. The electrochemical active bacteria sensitive to the heavy metal pollutants are used, so that the sensitivity of determining the biotoxicity of the heavy metal pollutants is expected to be improved, the application bottleneck of low sensitivity is overcome, and a technical support is provided for biotoxicity monitoring work in China.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which can solve the problem that the existing detection target lpxC of klebsiella pneumoniae is highly homologous with the sequence alignment of part of related bacteria (klebsiella oxytoca, enterobacter aerogenes and citrobacter freundii); based on the defect that a primer and probe combination designed by an existing target lpxC causes cross amplification of the bacteria and does not meet clinical requirements, and the situation that a combination of a drug-resistant gene mecA and klebsiella pneumoniae is not suitable for clinical scenes, by simultaneously identifying the klebsiella pneumoniae and common drug-resistant genes of the two bacteria, the drug-resistant genes of the two bacteria can be identified, and the drug-resistant genes of the two bacteria can be identified. The Klebsiella pneumoniae gene, namely a carbapenemase-producing drug-resistant gene KPC-2 and an extended-spectrum beta-lactamase-producing drug-resistant gene (ESBL) CTX-M-15, can be used for judging whether the Klebsiella pneumoniae is sensitive or drug-resistant Klebsiella pneumoniae and distinguishing specific drug-resistant phenotypes, so that more comprehensive and definite medication guidance can be provided for clinicians.

The invention discloses bacteriocin AM12LCIr as well as a preparation method and application of the bacteriocin AM12LCIr. The invention provides a bacteriocin AM12LCIr, the coding sequence of the bacteriocin AM12LCIr is composed of 46 amino acids, the relative molecular weight is 5067.73 Da, homology analysis shows that the bacteriocin AM12LCIr has the highest homology with class II bacteriocin LCI bacteriocin, but the AM12LCIr and LCI have obvious differences in structure and physicochemical properties, and the bacteriocin AM12LCIr belongs to a novel bacteriocin. According to the present invention, the bacteriocin AM12LCIr is subjected to heterologous expression, and the prepared recombinant protein has good inhibition effect on a variety of bacteria, can inhibit Escherichia coli, Listeria monocytogenes, Enterobacter aerogenes, Salmonella paratyphi B, Staphylococcus aureus and Bacillus cereus, has broad-spectrum antibacterial activity, can be used for preparing more antibacterial products, and has broad application prospects. The invention has important significance for clinically preventing and treating a plurality of pathogenic bacteria including escherichia coli.